<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-148877</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Certolizumab pegol</dc:title>
<dc:description xml:lang="en">Certolizumab pegol is a new anti-TNF drug formed by the Fab&#146; fragment of a humanized mouse monoclonal antibody bound to two molecules of polyethylene glycol. Certolizumab pegol recognizes and binds to human TNF-&amp;#945;, both in its soluble and membrane bound form, and has shown clinical efficacy in controlled trials for the treatment of RA and Crohns&#146; disease. In this review we summarize the structural characteristics and clinical efficacy data, as well as safety data of this anti-TNF agent in patients with RA (AU)</dc:description>
<dc:creator>Díaz González, José Federico</dc:creator>
<dc:creator>Delgado Frías, Esmeralda</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El certolizumab pegol es un nuevo fármaco anti-TNF formado por el fragmento Fab&#146; de un anticuerpo monoclonal murino humanizado unido a dos moléculas de polietilenglicol. El certolizumab pegol reconoce y neutraliza el TNF-&amp;#945; humano, soluble y unido a membrana, y ha demostrado eficacia clínica en ensayos controlados en la AR y en la enfermedad de Crohn. En esta revisión se resumen las características estructurales y los datos de eficacia clínica, de prevención del daño estructural, así como los datos de seguridad de este anti-TNF en pacientes con AR (AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);6(supl.3): 7-11, mar. 2011. tab, graf</dc:source>
<dc:identifier>ibc-148877</dc:identifier>
<dc:title xml:lang="es">Certolizumab pegol</dc:title>
<dc:subject>^d54857</dc:subject>
<dc:subject>^d54578^s22073</dc:subject>
<dc:subject>^d31092^s22006</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d1178^s22057</dc:subject>
<dc:subject>^d28302^s22057</dc:subject>
<dc:subject>^d1716^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201103</dc:date>
</metadata>
</record>
</ibecs-document>
